Skip to main content

Table 1 Patient characteristics, tumor characteristics and treatment modalities

From: The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy

  

Group A (n = 67)

Group B (n = 34)

Age (years)

mean (min-max)

56 (36–82)

58 (42–79)

Sex

M

60

31

 

F

7

3

cT stage

T1

2

1

 

T2

17

13

 

T3

27

7

 

T4

21

13

cN stage

N0

15

11

 

N1

12

3

 

N2

31

17

 

N3

9

3

Tumor site

glottic

3

2

 

supraglottic

16

10

 

hypopharynx

20

7

 

oropharynx

24

14

 

oral cavity

2

0

 

nasopharynx

2

1

Radiotherapy

66 Gy/ 2 Gy

20

4

 

70 Gy/1.4 Gy

4

1

 

70 Gy/2 Gy

41 (2+ cisplatinum)

28 (1+cisplatinum)

 

80.5 Gy/1.15 Gy

2 (1+cisplatinum)

1 (+ cisplatinum)

  1. Patient characteristics, tumor characteristics and treatment modalities are shown for Group A and Group B, both subgroups of the original study of CT-determined tumoral perfusion in patients with HNSCC treated by radiotherapy ± chemotherapy. Cisplatinum was given at a dose of 100 mg/m2 on days 1, 22 and 43.
  2. cT: clinical tumor stage. cN: clinical nodal stage. M: male. F: female. Gy: Gray.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us